Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.

doi:10.1016/j.lungcan.2015.06.017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2015

Nishiyama Akihiro, Katakami Nobuyuki, Yoshioka Hiroshige, Iwasaku Masahiro, Korogi Yohei, Hata Akito, Takeshita Jumpei, Otsuka Kojiro, Nishino Kazumi, Uchida Junji, Okuyama Takako, Namba Yoshinobu, Mori Masahide, Fujita Shiro, Morita Satoshi

Abstract excerpt

OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Erlotinib Hydrochloride

Share to Kaplan-Meier Estimate

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Pemetrexed

Share to Taxoids

Source

Open in PubMed

Identifiers

PMID: 26141215
DOI: 10.1016/j.lungcan.2015.06.017

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.PMID 26141215Read ↗

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.Semantic proximity Read ↗

Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.Semantic proximity Read ↗

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Semantic proximity Read ↗

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.Semantic proximity Read ↗

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.Semantic proximity Read ↗

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).Semantic proximity Read ↗

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.Semantic proximity Read ↗

Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.Semantic proximity Read ↗

Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).Semantic proximity Read ↗

A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).Semantic proximity Read ↗

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.